These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 32224561)

  • 21. Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison.
    Usmani SZ; Diels J; Ito T; Mehra M; Khan I; Lam A
    Am J Hematol; 2017 Aug; 92(8):E146-E152. PubMed ID: 28474745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Daratumumab for the Treatment of Multiple Myeloma.
    Plesner T; Krejcik J
    Front Immunol; 2018; 9():1228. PubMed ID: 29915586
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of novel therapies in high-molecular-risk multiple myeloma.
    Lancman G; Tremblay D; Barley K; Barlogie B; Cho HJ; Jagannath S; Madduri D; Moshier E; Parekh S; Chari A
    Clin Adv Hematol Oncol; 2017 Nov; 15(11):870-879. PubMed ID: 29200420
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis.
    Pick M; Vainstein V; Goldschmidt N; Lavie D; Libster D; Gural A; Grisariu S; Avni B; Ben Yehuda D; Gatt ME
    Eur J Haematol; 2018 May; 100(5):494-501. PubMed ID: 29453884
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Once-weekly
    Bringhen S; Mina R; Petrucci MT; Gaidano G; Ballanti S; Musto P; Offidani M; Spada S; Benevolo G; Ponticelli E; Galieni P; Cavo M; Di Toritto TC; Di Raimondo F; Montefusco V; Palumbo A; Boccadoro M; Larocca A
    Haematologica; 2019 Aug; 104(8):1640-1647. PubMed ID: 30733270
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiotoxicity of Carfilzomib in Two Japanese Patients with Relapsed Multiple Myeloma.
    Ikoma T; Saotome M; Sano M; Suwa K; Naruse Y; Ohtani H; Urushida T; Nagata Y; Ono T; Maekawa Y
    Intern Med; 2019 Jun; 58(11):1577-1581. PubMed ID: 30713316
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin?
    Marchica V; Accardi F; Storti P; Mancini C; Martella E; Dalla Palma B; Bolzoni M; Todoerti K; Marcatti M; Schifano C; Bonomini S; Sammarelli G; Neri A; Ponzoni M; Aversa F; Giuliani N
    Int J Hematol; 2017 Jan; 105(1):104-108. PubMed ID: 27699576
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advances in the diagnosis and management of myeloma.
    Greipp PR
    Semin Hematol; 1992 Jul; 29(3 Suppl 2):24-45. PubMed ID: 1509293
    [No Abstract]   [Full Text] [Related]  

  • 29. Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone.
    Manasanch EE; de Larrea CF; Zingone A; Steinberg SM; Kwok M; Tageja N; Bhutani M; Kazandjian D; Roschewski M; Wu P; Carter G; Zuchlinski D; Mulquin M; Lamping L; Costello R; Burton D; Gil LA; Figg WD; Maric I; Calvo KR; Yuan C; Stetler-Stevenson M; Korde N; Landgren O
    Leuk Lymphoma; 2017 Mar; 58(3):639-645. PubMed ID: 27687480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjusted comparison of daratumumab monotherapy versus real-world historical control data from the Czech Republic in heavily pretreated and highly refractory multiple myeloma patients.
    Jelínek T; Maisnar V; Pour L; Špička I; Minařík J; Gregora E; Kessler P; Sýkora M; Fraňková H; Adamová D; Wróbel M; Mikula P; Jarkovský J; Diels J; Gatopoulou X; Veselá Š; Besson H; Brožová L; Ito T; Hájek R
    Curr Med Res Opin; 2018 May; 34(5):775-783. PubMed ID: 29172760
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiple myeloma: new uses for available agents, excitement for the future.
    Anderson KC
    J Natl Compr Canc Netw; 2015 May; 13(5 Suppl):694-6. PubMed ID: 25995433
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Carfilzomib in multiple myeloma.
    Andreu-Vieyra C; Berenson JR
    Expert Opin Biol Ther; 2014 Nov; 14(11):1685-99. PubMed ID: 25170966
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emerging therapies in multiple myeloma.
    El-Amm J; Tabbara IA
    Am J Clin Oncol; 2015 Jun; 38(3):315-21. PubMed ID: 23934133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Electrophoretic patterns post daratumumab.
    Sheldon J; Wheeler RD; Powles R
    Ann Clin Biochem; 2018 Mar; 55(2):299-301. PubMed ID: 28490184
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of carfilzomib in the treatment of multiple myeloma.
    Khan RZ; Badros A
    Expert Rev Hematol; 2012 Aug; 5(4):361-72. PubMed ID: 22992230
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A practical review on carfilzomib in multiple myeloma.
    Muchtar E; Gertz MA; Magen H
    Eur J Haematol; 2016 Jun; 96(6):564-77. PubMed ID: 26893241
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma.
    Vij R; Wang M; Jagannath S; Niesvizky R; Jakubowiak AJ; Kavalerchik E; Huang M; Siegel DS
    Leuk Lymphoma; 2015; 56(10):2959-61. PubMed ID: 25699653
    [No Abstract]   [Full Text] [Related]  

  • 38. Carfilzomib (Kyprolis°) in multiple myeloma.
    Prescrire Int; 2017 May; 26(182):120. PubMed ID: 30730668
    [No Abstract]   [Full Text] [Related]  

  • 39. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.
    Lonial S; Weiss BM; Usmani SZ; Singhal S; Chari A; Bahlis NJ; Belch A; Krishnan A; Vescio RA; Mateos MV; Mazumder A; Orlowski RZ; Sutherland HJ; Bladé J; Scott EC; Oriol A; Berdeja J; Gharibo M; Stevens DA; LeBlanc R; Sebag M; Callander N; Jakubowiak A; White D; de la Rubia J; Richardson PG; Lisby S; Feng H; Uhlar CM; Khan I; Ahmadi T; Voorhees PM
    Lancet; 2016 Apr; 387(10027):1551-1560. PubMed ID: 26778538
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Daratumumab in multiple myeloma.
    Rajkumar SV
    Lancet; 2016 Apr; 387(10027):1490-1492. PubMed ID: 26778537
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.